Byotrol (LSE:BYOT) Total Receivables : £1.22 Mil (As of Sep. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Byotrol Total Receivables?

Byotrol's Total Receivables for the quarter that ended in Sep. 2023 was £1.22 Mil.

Byotrol Total Receivables Historical Data

The historical data trend for Byotrol's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Byotrol Total Receivables Chart

Byotrol Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Receivables

Get a 7-Day Free Trial

1.50

1.90

1.61

1.94

1.67

Byotrol Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Total Receivables	Get a 7-Day Free Trial															1.77	1.94	1.65	1.67	1.22

Byotrol Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Byotrol Total Receivables Related Terms

Thank you for viewing the detailed overview of Byotrol's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Byotrol (LSE:BYOT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Byotrol PLC (LSE:BYOT) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

B7Y:Germany

Address

Building 303 (Ashton), Pool Lane, Thornton Science Park, Ince, Chester, GBR, CH2 4NU

Website

https://www.byotrolplc.com

Byotrol PLC is a developer of consumer and professional antimicrobial technologies and products. It is engaged in the development, patenting, licensing, and sale of anti-microbial products and technologies for business and consumer use. It operates in two reportable segments, being Professional (including Human Health, Animal Health, Facilities Management, and Food & Beverage), and Consumer (Including Household, Skin Care, and Pet Care). Its customers are based in the UK, North America, Asia, and the Rest of the World. The company generates key revenue from product sales - sale of anti-microbial technology and includes Royalty and licensing income.

Byotrol (LSE:BYOT) Headlines

No Headlines